Contrasting MindWalk (HYFT) & Its Rivals

MindWalk (NASDAQ:HYFT) is one of 458 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its peers? We will compare MindWalk to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Profitability

This table compares MindWalk and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MindWalk	-145.58%	-56.75%	-31.55%
MindWalk Competitors	-2,662.14%	-363.93%	-42.95%

Earnings & Valuation

This table compares MindWalk and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MindWalk	$17.59 million	-$21.69 million	-2.18
MindWalk Competitors	$432.12 million	-$67.78 million	-10.63

MindWalk’s peers have higher revenue, but lower earnings than MindWalk. MindWalk is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations and price targets for MindWalk and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1	1	0	0	1.50
MindWalk Competitors	4898	9967	15989	376	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 65.78%. Given MindWalk’s peers stronger consensus rating and higher probable upside, analysts plainly believe MindWalk has less favorable growth aspects than its peers.

Risk and Volatility

MindWalk has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, MindWalk’s peers have a beta of 5.43, suggesting that their average stock price is 443% more volatile than the S&P 500.

Institutional & Insider Ownership

6.7% of MindWalk shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 6.8% of MindWalk shares are held by company insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MindWalk peers beat MindWalk on 8 of the 13 factors compared.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.